Nevertheless, chronic low-grade inflammation associated with MASLD, driven by IL-6 or IL-1β cytokines released from adipose tissue macrophages, could counteract these protective effects of IL-17 (151). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.